Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more
Market Cap & Net Worth: Eris Lifesciences Limited (ERIS)
Eris Lifesciences Limited (NSE:ERIS) has a market capitalization of $2.01 Billion (₹174.41 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #9103 globally and #364 in its home market, demonstrating a -6.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eris Lifesciences Limited's stock price ₹1280.40 by its total outstanding shares 136216891 (136.22 Million).
Eris Lifesciences Limited Market Cap History: 2017 to 2026
Eris Lifesciences Limited's market capitalization history from 2017 to 2026. Data shows growth from $1.21 Billion to $2.01 Billion (9.50% CAGR).
Index Memberships
Eris Lifesciences Limited is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$1.27 Trillion | 0.05% | #314 of 500 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.73 Billion | 0.12% | #223 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.32 Trillion | 0.05% | #322 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$188.65 Billion | 0.34% | #106 of 250 |
Weight: Eris Lifesciences Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eris Lifesciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eris Lifesciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Eris Lifesciences Limited's market cap is 0.08 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.67x
Eris Lifesciences Limited's market cap is 0.67 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.21 Billion | $7.25 Billion | $2.42 Billion | 0.17x | 0.50x |
| 2018 | $1.04 Billion | $8.56 Billion | $2.94 Billion | 0.12x | 0.35x |
| 2019 | $719.28 Million | $9.67 Billion | $2.91 Billion | 0.07x | 0.25x |
| 2020 | $895.39 Million | $10.58 Billion | $2.96 Billion | 0.08x | 0.30x |
| 2021 | $1.18 Billion | $11.93 Billion | $3.55 Billion | 0.10x | 0.33x |
| 2022 | $1.02 Billion | $13.26 Billion | $4.06 Billion | 0.08x | 0.25x |
| 2023 | $1.43 Billion | $16.62 Billion | $3.82 Billion | 0.09x | 0.37x |
| 2024 | $2.16 Billion | $19.91 Billion | $3.92 Billion | 0.11x | 0.55x |
| 2025 | $2.37 Billion | $28.79 Billion | $3.52 Billion | 0.08x | 0.67x |
Competitor Companies of ERIS by Market Capitalization
Companies near Eris Lifesciences Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Eris Lifesciences Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Eris Lifesciences Limited Historical Marketcap From 2017 to 2026
Between 2017 and today, Eris Lifesciences Limited's market cap moved from $1.21 Billion to $ 2.01 Billion, with a yearly change of 9.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹2.01 Billion | -14.96% |
| 2025 | ₹2.37 Billion | +9.60% |
| 2024 | ₹2.16 Billion | +50.96% |
| 2023 | ₹1.43 Billion | +40.59% |
| 2022 | ₹1.02 Billion | -13.93% |
| 2021 | ₹1.18 Billion | +32.10% |
| 2020 | ₹895.39 Million | +24.48% |
| 2019 | ₹719.28 Million | -31.02% |
| 2018 | ₹1.04 Billion | -13.50% |
| 2017 | ₹1.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Eris Lifesciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.01 Billion USD |
| MoneyControl | $2.01 Billion USD |
| MarketWatch | $2.01 Billion USD |
| marketcap.company | $2.01 Billion USD |
| Reuters | $2.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.